CEINGE Biotecnologie Avanzate
Functional proteomics for identification of miRNA targets
Contact person details
Name:
ZAMBRANO , Nicola ( PhD)
Name of
Organisation:
CEINGE Biotecnologie Avanzate
URL:
http://www.ceinge.unina.it/~zambrano/index.html
E-mail:
Contact
Telephone:
+39-081-3737877
Fax number:
+39-081-3737808
Collaboration
Type: Company Expertise
Title: Functional proteomics for identification of miRNA targets
Participation: Type A
Type Details: The functions of miRNAs in normal conditions and in the altered
biological processes leading to various diseases (cancer, cardiovascular diseases
etc.) are clearly emerging. miRNAs usually lead to translation inhibition of targeted
mRNAs; due to their ability to bind to multiple mRNA targets, their expression gives
rise to altered protein expression profiles, which are relevant for the elicitation of
their functions through altered expression of selected proteins. Bioinformatics can
predict a genome-wide scenario of potential miRNA targets; functional proteomics,
instead, will give an effective picture, more focused to the relevant targets, in the
appropriate (cellular or animal) model. Implementation of subcellular and/or
biochemical fractionations will also improve the identification of protein targets
expressed at lower levels. Combination of bioinformatics and functional proteomics
will indeed generate the most effective representation of miRNA functions in normal,
as well as diseased conditions.
Our Unit houses a complete workstation for differential proteomic analysis, based on
bi-dimensional separation of proteins and fluorescent labelling (2D-DIGE). Taking
advantage of the DecyderTM software, DIGE technology allows to obtain statistically
and biologically relevant protein difference ratios, from any biological source.
Automated spot picking will give purified spots for mass spectrometry-based
identification of the differentially expressed miRNA target proteins.
We can offer our collaboration, skills and technologies, to generate proteomic maps
from cells or animal models treated with miRNAs mimetics or miRNA inhibitors
(antagomir), either synthetic or encoded by retroviral/lentiviral vectors; this will
result in the experimental identification of the relevant targets for the miRNAs of
interest.
Programme: TECHNOLOGY PLATFORMS , FP7 , FP7-COOPERATION , FP7-PEOPLE ,
FP7-HEALTH
Instruments: NoE Networks of Excellence,CP-FP Small or medium-scale focused
research project,CP-IP Large-scale integrating project,CSA-ERA-Plus ERA-NET
Plus,ERC-ER1 Experienced researchers 1st stage,NULLERC-ER2 Experienced
researchers 2nd stage,CP-SICA Collaborative project for specific cooperation actions
dedicated to international cooperation partner countries (SICA)
Research interest:
Expiry Date: 2009-01-25
Workprogramme area(s)/key action(s):
(FP7-HEALTH HEALTH-2007-2) Translating research for human health
(FP7-HEALTH HEALTH-2007-2.4.2) Cardiovascular disease
(FP7-PEOPLE PEOPLE-2007-2-1.IEF) Marie Curie Action: "Intra-European Fellowships
for Career Development"
(FP7-HEALTH HEALTH-2007-2.4.3) Diabetes and obesity
(FP7-HEALTH HEALTH-1.1) High-throughput research
(FP7-HEALTH HEALTH-2007-2.2.2) Human development and ageing
(FP7-HEALTH HEALTH-2007-2.2) Research on the brain and related diseases, human
development and ageing
(FP7-HEALTH HEALTH-2007-2.3.3) Potentially new and re-emerging epidemics
(FP7-HEALTH HEALTH-2007-2.1) Integrating biological data and processes: largescale data gathering, systems biology
(FP7-HEALTH HEALTH-2007-2.3.4) Neglected infectious diseases
(FP7-HEALTH HEALTH-2007-4) Other Actions across the Health Theme
(FP7-HEALTH HEALTH-2007-2.3.2) HIV/AIDS, malaria and tuberculosis
(FP7-HEALTH HEALTH-2007-2.4.4) Rare diseases
(FP7-HEALTH HEALTH-2007-1.3) Predicting suitability, safety and efficacy of
therapies
(FP7-HEALTH HEALTH-1) Biotechnology, generic tools and medical technologies for
human health
(FP7-PEOPLE PEOPLE-2007-2-3.COFUND) Marie Curie Action: "Co-funding of
Regional, National and International Programmes "
(FP7-PEOPLE PEOPLE-2007-1-1.ITN) Marie Curie Action: "Networks for Initial
Training"
(FP7-PEOPLE PEOPLE-1) Initial training of researchers
(FP7-HEALTH HEALTH-2007-2.3) Translational research in major infectious diseases:
To confront major threats to public health
(FP7-HEALTH HEALTH-2007-2.1.2) Systems biology
(FP7-HEALTH HEALTH-2007-2.2.1) Brain and brain-related diseases
(FP7-HEALTH HEALTH-2007-2.4) Translational research in other major diseases
(FP7-HEALTH HEALTH-2007-2.3.1) Anti-microbial drug resistance including fungal
pathogens
(FP7-HEALTH HEALTH-2007-1.4) Innovative therapeutic approaches and
interventions
(FP7-HEALTH HEALTH-2007-3.1) Translating the results of clinical research outcome
into clinical practice including better use of medicines, and appropriate use of
behavioural and organisational interventions and new health therapies and
technologies
(FP7-PEOPLE PEOPLE-2) Life-long training and career development
(FP7-HEALTH HEALTH-2007-2.4.5) Other chronic diseases
(FP7-HEALTH HEALTH-2007-1.2) Detection, diagnosis and monitoring
(FP7-PEOPLE PEOPLE-2007-3-1.IAPP) Marie Curie Action: "Industry-Academia
Partnerships and Pathways"
(FP7-PEOPLE PEOPLE-2007-2-2.ERG) Marie Curie Action: "European Reintegration
Grants"
(FP7-HEALTH HEALTH-2007-2.4.1) Cancer
Target Partner
Expertise:
Our Unit aims to join consortia "under construction" for collaborative projects,
addressing biological processes relevant to health and diseases, requiring the
definition of proteomic signatures, in clinical and/or experimental settings, for
identification and validation of miRNA targets.
Country: Any country
Organization Details
Name:
CEINGE Biotecnologie Avanzate
Department:
Address:
CEINGE Biotecnologie Avanzate
Via Comunale Margherita, 482
80145
Napoli
ITALIA
Type:
Research, Education
Number of
Employees:
50 - 249
Details:
Keywords:
Partners already
acquired:
2D-DIGE
antagomir
micro RNA
gene expression
animal model